The global acute bacterial skin and skin structure infections market size was estimated to be USD 1.34 billion in 2023 and is expected to reach USD 2.31 billion by 2034 with a CAGR of 5.12% during the forecast period 2024-2034. Rising prevalence of acute bacterial skin and skin structure infections (ABSSSI), expanding access to healthcare, rapid technological advancements, growing awareness of ABSSSI, and collaborations and partnerships will drive market growth.
The market for acute bacterial skin and skin structure infections is expanding as a result of an increase in the frequency of bacterial skin infections, particularly those brought on by drug-resistant strains. A greater occurrence of these infections might be caused by variables such as immunocompromised states, skin injuries, and inadequate hygiene. For instance, in August 2023, Pfizer Inc. was granted FDA clearance for VEKLURY (omalizumab) injectable, which is intended to treat persistent hives that do not respond to traditional treatment methods. Enhancing general skin health may have an indirect benefit on managing ABSSSI.
By type of infection, the community-acquired ABSSSI segment accounted for the highest revenue-grossing segment in the global acute bacterial skin and skin structure infections market in 2023 owing to the increasing incidence of skin infections within community settings, rising awareness among healthcare professionals and the public about the significance of early diagnosis and treatment, and the development of effective antibiotics tailored for community-acquired pathogens. For instance, in September 2023, Sentieon Therapeutics and GlaxoSmithKline plc collaborated to explore new medicines for Gram-negative bacterial infections, which may have uses in the treatment of ABSSSI. Additionally, the hospital-acquired ABSSSI segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of healthcare-associated infections, the rise in the number of hospitalized patients with compromised immune systems, and the heightened awareness regarding the importance of infection prevention and control measures within healthcare facilities.
By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global acute bacterial skin and skin structure infections market in 2023 owing to the increasing preference for outpatient care, the convenience and patient compliance associated with oral antibiotic formulations, and the continuous development of orally administered antibiotics that offer effective and accessible treatment options for individuals with mild to moderate cases of ABSSSI. For instance, Novartis AG presented promising Phase 2a results in October 2023 for the use of the new antibiotic NIBRIO (OM1908) in the treatment of S. aureus infections, including ABSSSI. Additionally, the parenteral segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing severity of acute bacterial skin and skin structure infections, the need for rapid and targeted intervention in critical cases, and advancements in parenteral drug formulations that provide enhanced bioavailability and efficacy.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global acute bacterial skin and skin structure infections market in 2023 owing to the centralized role of hospitals in managing severe cases of ABSSSI, the increased prevalence of hospitalized patients requiring specialized treatment, and the convenient access to a diverse range of antibiotics within hospital pharmacy settings. For instance, in March 2023, Allergan published results at the American Academy of Dermatology meeting indicating the effectiveness of VIBATIV (telavancin) for the treatment of ABSSSI caused by S. aureus, particularly methicillin-resistant S. aureus (MRSA). AbbVie Inc. is purchasing Allergan plc. Additionally, the retail pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend of outpatient care for managing mild to moderate cases of acute bacterial skin and skin structure infections (ABSSSI), the expanding role of community pharmacies in providing accessible healthcare services, and the growing emphasis on self-administration and convenience.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high prevalence of acute bacterial skin and skin structure infections (ABSSSI), robust research and development activities, and a proactive approach towards adopting advanced medical treatments. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of acute bacterial skin and skin structure infections (ABSSSI), rising healthcare awareness, expanding access to medical services, and a growing emphasis on improving healthcare infrastructure. For instance, in November 2023, Sun Pharmaceutical Industries Ltd. introduced Cefdinir to the Indian market to treat a variety of bacterial infections, including ABSSSI.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
The market for acute bacterial skin and skin structure infections is expanding as a result of an increase in the frequency of bacterial skin infections, particularly those brought on by drug-resistant strains. A greater occurrence of these infections might be caused by variables such as immunocompromised states, skin injuries, and inadequate hygiene. For instance, in August 2023, Pfizer Inc. was granted FDA clearance for VEKLURY (omalizumab) injectable, which is intended to treat persistent hives that do not respond to traditional treatment methods. Enhancing general skin health may have an indirect benefit on managing ABSSSI.
By type of infection, the community-acquired ABSSSI segment accounted for the highest revenue-grossing segment in the global acute bacterial skin and skin structure infections market in 2023 owing to the increasing incidence of skin infections within community settings, rising awareness among healthcare professionals and the public about the significance of early diagnosis and treatment, and the development of effective antibiotics tailored for community-acquired pathogens. For instance, in September 2023, Sentieon Therapeutics and GlaxoSmithKline plc collaborated to explore new medicines for Gram-negative bacterial infections, which may have uses in the treatment of ABSSSI. Additionally, the hospital-acquired ABSSSI segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of healthcare-associated infections, the rise in the number of hospitalized patients with compromised immune systems, and the heightened awareness regarding the importance of infection prevention and control measures within healthcare facilities.
By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global acute bacterial skin and skin structure infections market in 2023 owing to the increasing preference for outpatient care, the convenience and patient compliance associated with oral antibiotic formulations, and the continuous development of orally administered antibiotics that offer effective and accessible treatment options for individuals with mild to moderate cases of ABSSSI. For instance, Novartis AG presented promising Phase 2a results in October 2023 for the use of the new antibiotic NIBRIO (OM1908) in the treatment of S. aureus infections, including ABSSSI. Additionally, the parenteral segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing severity of acute bacterial skin and skin structure infections, the need for rapid and targeted intervention in critical cases, and advancements in parenteral drug formulations that provide enhanced bioavailability and efficacy.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global acute bacterial skin and skin structure infections market in 2023 owing to the centralized role of hospitals in managing severe cases of ABSSSI, the increased prevalence of hospitalized patients requiring specialized treatment, and the convenient access to a diverse range of antibiotics within hospital pharmacy settings. For instance, in March 2023, Allergan published results at the American Academy of Dermatology meeting indicating the effectiveness of VIBATIV (telavancin) for the treatment of ABSSSI caused by S. aureus, particularly methicillin-resistant S. aureus (MRSA). AbbVie Inc. is purchasing Allergan plc. Additionally, the retail pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend of outpatient care for managing mild to moderate cases of acute bacterial skin and skin structure infections (ABSSSI), the expanding role of community pharmacies in providing accessible healthcare services, and the growing emphasis on self-administration and convenience.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high prevalence of acute bacterial skin and skin structure infections (ABSSSI), robust research and development activities, and a proactive approach towards adopting advanced medical treatments. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of acute bacterial skin and skin structure infections (ABSSSI), rising healthcare awareness, expanding access to medical services, and a growing emphasis on improving healthcare infrastructure. For instance, in November 2023, Sun Pharmaceutical Industries Ltd. introduced Cefdinir to the Indian market to treat a variety of bacterial infections, including ABSSSI.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type of Infection, Route of Administration, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Acute Bacterial Skin and Skin Structure Infections Market Report 2023 - 2034
Acute Bacterial Skin and Skin Structure Infections Market Analysis & Forecast by Type of Infection 2023 - 2034 (Revenue USD Bn)
- Hospital-acquired ABSSI
- Community-acquired ABSSI
Acute Bacterial Skin and Skin Structure Infections Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Oral
- Parenteral
- Topical
Acute Bacterial Skin and Skin Structure Infections Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Acute Bacterial Skin and Skin Structure Infections Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Acute Bacterial Skin and Skin Structure Infections Market: Type of Infection Estimates & Trend Analysis
8. Acute Bacterial Skin and Skin Structure Infections Market: Route of Administration Estimates & Trend Analysis
9. Acute Bacterial Skin and Skin Structure Infections Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Acute Bacterial Skin and Skin Structure Infections Market
12. Europe Global Acute Bacterial Skin and Skin Structure Infections Market
13. Asia Pacific Global Acute Bacterial Skin and Skin Structure Infections Market
14. Latin America Global Acute Bacterial Skin and Skin Structure Infections Market
15. MEA Global Acute Bacterial Skin and Skin Structure Infections Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Pfizer Inc.
- Merck & Co. Inc.
- GlaxoSmithKline plc
- Novartis AG
- Allergan plc (acquired by AbbVie Inc.)
- Johnson & Johnson
- Bristol Myers Squibb Company
- Cubist Pharmaceuticals (acquired by Merck & Co.)
- Teva Pharmaceutical Industries Ltd.
- Melinta Therapeutics Inc.
- F. Hoffmann-La Roche Ltd.
- Cempra Inc. (acquired by Melinta Therapeutics)
- Sun Pharmaceutical Industries Ltd.
- Actavis Inc. (now part of Teva Pharmaceutical Industries Ltd.)
- Daiichi Sankyo Company Limited.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 1.34 Billion |
| Forecasted Market Value ( USD | $ 2.31 Billion |
| Compound Annual Growth Rate | 5.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
